Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction.
Llevadot J, Giugliano RP, Antman EM, Wilcox RG, Gurfinkel EP, Henry T, McCabe CH, Charlesworth A, Thompson S, Nicolau JC, Tebbe U, Sadowski Z, Braunwald E; InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early) II Investigators. Llevadot J, et al. Among authors: gurfinkel ep. Eur Heart J. 2001 Nov;22(22):2104-15. doi: 10.1053/euhj.2001.2622. Eur Heart J. 2001. PMID: 11686667 Clinical Trial.
Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J, Parkhomenko A, Molhoek P, Mohanavelu S, Morrow DA, Antman EM. Giraldez RR, et al. Among authors: gurfinkel ep. Eur Heart J. 2007 Jul;28(13):1566-73. doi: 10.1093/eurheartj/ehm179. Epub 2007 Jun 11. Eur Heart J. 2007. PMID: 17562672 Clinical Trial.
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II.
Giugliano RP, Llevadot J, Wilcox RG, Gurfinkel EP, McCabe CH, Charlesworth A, Thompson SL, Antman EM, Braunwald E; InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early) II Investigators. Giugliano RP, et al. Among authors: gurfinkel ep. Eur Heart J. 2001 Sep;22(18):1702-15. doi: 10.1053/euhj.2001.2583. Eur Heart J. 2001. PMID: 11511120 Clinical Trial.
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Antman EM, et al. Among authors: gurfinkel ep. Circulation. 1999 Oct 12;100(15):1593-601. doi: 10.1161/01.cir.100.15.1593. Circulation. 1999. PMID: 10517729 Clinical Trial.
Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.
Cohen M, Antman EM, Gurfinkel EP, Radley D; ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) 11B Investigators. Cohen M, et al. Among authors: gurfinkel ep. J Thromb Thrombolysis. 2001 Dec;12(3):199-206. doi: 10.1023/a:1015259706522. J Thromb Thrombolysis. 2001. PMID: 11981102
102 results